全文获取类型
收费全文 | 582篇 |
免费 | 28篇 |
国内免费 | 2篇 |
专业分类
耳鼻咽喉 | 15篇 |
儿科学 | 17篇 |
妇产科学 | 23篇 |
基础医学 | 89篇 |
口腔科学 | 8篇 |
临床医学 | 62篇 |
内科学 | 96篇 |
皮肤病学 | 6篇 |
神经病学 | 65篇 |
特种医学 | 12篇 |
外科学 | 107篇 |
综合类 | 4篇 |
一般理论 | 2篇 |
预防医学 | 29篇 |
眼科学 | 15篇 |
药学 | 41篇 |
肿瘤学 | 21篇 |
出版年
2021年 | 9篇 |
2020年 | 10篇 |
2019年 | 14篇 |
2018年 | 10篇 |
2017年 | 13篇 |
2016年 | 6篇 |
2014年 | 12篇 |
2013年 | 18篇 |
2012年 | 26篇 |
2011年 | 21篇 |
2010年 | 12篇 |
2009年 | 14篇 |
2008年 | 26篇 |
2007年 | 35篇 |
2006年 | 34篇 |
2005年 | 31篇 |
2004年 | 35篇 |
2003年 | 30篇 |
2002年 | 22篇 |
2001年 | 26篇 |
2000年 | 15篇 |
1999年 | 25篇 |
1998年 | 3篇 |
1997年 | 5篇 |
1995年 | 3篇 |
1992年 | 6篇 |
1991年 | 14篇 |
1990年 | 9篇 |
1989年 | 11篇 |
1988年 | 9篇 |
1987年 | 4篇 |
1986年 | 7篇 |
1985年 | 9篇 |
1984年 | 6篇 |
1983年 | 5篇 |
1982年 | 3篇 |
1981年 | 7篇 |
1980年 | 6篇 |
1978年 | 5篇 |
1977年 | 4篇 |
1976年 | 4篇 |
1975年 | 3篇 |
1974年 | 9篇 |
1973年 | 2篇 |
1972年 | 3篇 |
1971年 | 4篇 |
1970年 | 5篇 |
1969年 | 3篇 |
1968年 | 4篇 |
1966年 | 3篇 |
排序方式: 共有612条查询结果,搜索用时 31 毫秒
101.
Maheshwari S 《Indian journal of ophthalmology》2005,53(1):53-55
PURPOSE: To describe the technique of split-conjunctival grafts (SCG) for double-head pterygia and to evaluate its postoperative outcome. METHOD: A retrospective analysis of seven eyes with primary double-head pterygium was done. All eyes received pterygium excision with split-conjunctival grafts harvested from the superior quadrant. All patients were followed up for recurrence of the lesion and incidence of complications. RESULTS: No recurrence was noted with a mean follow-up of 17.7 +/- 6 months. CONCLUSION: Split-conjunctival graft is a useful procedure for double-head pterygium. 相似文献
102.
103.
Sejal Bavishi BA Kenneth Wong MD Thamani Delgardo BA RTT Araz Marachelian MD Soumen Khatua MD 《Pediatric blood & cancer》2010,54(1):170-172
Epidermolysis bullosa simplex (EBS) is a heritable skin disorder characterized by skin fragility and blistering. While its most severe variant, dystrophic epidermolysis bullosa (DEB) is associated with squamous cell carcinoma (SCC), the development of extracutaneous neoplasms in EBS is extremely rare. We report a novel case of supratentorial primitive neuroectodermal tumor (sPNET) in a 7‐year male with EBS. Experience of radiation therapy and its challenges in children with EBS has rarely been reported. Pediatr Blood Cancer 2010; 54:170–172. © 2009 Wiley‐Liss, Inc. 相似文献
104.
Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease: a randomized controlled trial 总被引:13,自引:0,他引:13
105.
106.
Neuropeptide S stimulates the hypothalamo-pituitary-adrenal axis and inhibits food intake 总被引:3,自引:0,他引:3
Smith KL Patterson M Dhillo WS Patel SR Semjonous NM Gardiner JV Ghatei MA Bloom SR 《Endocrinology》2006,147(7):3510-3518
Neuropeptide S (NPS) is a recently discovered peptide shown to be involved in the modulation of arousal and fear responses. It has also been shown that lateral ventricle administration of NPS causes a significant decrease in food intake. Neuropeptides involved in the modulation of arousal have been shown to be involved in the regulation of the hypothalamo-pituitary adrenal (HPA) axis and food intake. In this study, we have examined the effect of intracerebroventricular (ICV) administration of NPS on behavior, regulation of the HPA axis, and food intake. ICV NPS significantly increased plasma ACTH and corticosterone 10 and 40 min after injection, respectively. A single ICV injection of NPS caused a significant increase in rearing activity as well as ambulatory movement for up to 45 min after injection. We then studied the effect of paraventricular nucleus (PVN) administration of NPS on the regulation of the HPA axis, behavior, and food intake. There was a significant increase in plasma ACTH and corticosterone after a single NPS PVN injection. Incubation of hypothalamic explants with increasing concentrations of NPS caused a significant increase in CRH and arginine vasopressin release. In addition, PVN administration of NPS dose-dependently inhibited food intake in the first hour after injection, although no effect on food intake was seen after this time. PVN administration of NPS caused a significant increase in rearing activity. These data demonstrate a novel role for NPS in the stimulation of the HPA axis. 相似文献
107.
Sleep deprivation for one night induces mood improvement in depressed patients, an action that probably involves the serotonergic (5-HT) system. In animals, sleep deprivation and pharmacologic treatment with antidepressants exert similar effects on 5-HT neurotransmission, notably functional desensitization of 5-HT1A autoreceptors located on 5-HT neurons in the dorsal raphe nucleus (DRN). However, in stressful conditions, corticosterone can also induce a desensitization of these autoreceptors. STUDY OBJECTIVES: To investigate the mechanisms of this adaptation during sleep deprivation and the possible involvement of corticosterone, we studied the effects of an 18-hour sleep deprivation, by forced locomotion, on 5-HT1A receptor-mediated firing response of DRN 5-HT neurons in transgenic mice with impaired glucocorticoid-receptor expression (GR-i) and in wild-type animals. We also examined the effects of chronic treatment with the antidepressant drug fluoxetine in the same paradigm. MEASUREMENTS AND RESULTS: In both wild-type and GR-i mice, the 18-hour sleep deprivation or fluoxetine treatment had no effect on the spontaneous firing of 5-HT neurons recorded under anesthesia. However, sleep deprivation decreased the potency of the 5-HT1A agonist 8-OH-DPAT to inhibit 5-HT neuronal firing in wild-type mice, whereas it had no effect in GR-i animals. Conversely, after chronic fluoxetine treatment, the induced reduction of this 5-HT1A autoreceptor-driven response was of larger amplitude in GR-i than in wild-type mice. CONCLUSIONS: These data suggest that glucocorticoid-receptor activation by corticosterone participates in the antidepressant-like adaptive changes in 5-HT1A autoreceptors in sleep-deprived mice. On the other hand, GR-i animals exhibited enhanced 5-HT1A autoreceptor desensitization induced by fluoxetine, in line with data in other animal models of depression. 相似文献
108.
Saglani S Bush A Payne D 《The Journal of allergy and clinical immunology》2006,117(4):955; author reply 955
109.
Zoë Urry Emma S. Chambers Emmanuel Xystrakis Sarah Dimeloe David F. Richards Leona Gabryšová Jillian Christensen Atul Gupta Sejal Saglani Andrew Bush Anne O'Garra Zarin Brown Catherine M. Hawrylowicz 《European journal of immunology》2012,42(10):2697-2708
1α,25‐Dihydroxyvitamin D3 (1α25VitD3) has potent immunomodulatory properties. We have previously demonstrated that 1α25VitD3 promotes human and murine IL‐10‐secreting CD4+ T cells. Because of the clinical relevance of this observation, we characterized these cells further and investigated their relationship with Foxp3+ regulatory T (Treg) cells. 1α25VitD3 increased the frequency of both Foxp3+ and IL‐10+ CD4+T cells in vitro. However, Foxp3 was increased at high concentrations of 1α25VitD3 and IL‐10 at more moderate levels, with little coexpression of these molecules. The Foxp3+ and IL‐10+ T‐cell populations showed comparable suppressive activity. We demonstrate that the enhancement of Foxp3 expression by 1α25VitD3 is impaired by IL‐10. 1α25VitD3 enables the selective expansion of Foxp3+ Treg cells over their Foxp3? T‐cell counterparts. Equally, 1α25VitD3 maintains Foxp3+ expression by sorted populations of human and murine Treg cells upon in vitro culture. A positive in vivo correlation between vitamin D status and CD4+Foxp3+ T cells in the airways was observed in a severe pediatric asthma cohort, supporting the in vitro observations. In summary, we provide evidence that 1α25VitD3 enhances the frequency of both IL‐10+ and Foxp3+ Treg cells. In a translational setting, these data suggest that 1α25VitD3, over a broad concentration range, will be effective in enhancing the frequency of Treg cells. 相似文献
110.
Yadav Y Maclean ED Bhattacharyya A Parmar VS Balzarini J Barden CJ Too CK Jha A 《European journal of medicinal chemistry》2011,46(9):3858-3866
In an systematic attempt to develop novel Selective Estrogen Receptor Modulators (SERMs), chiral 1-((4-(2-(dialkylamino)ethoxy)phenyl)(2-hydroxynaphthalen-1-yl)methyl)piperidin-4-ols were designed based on an accepted pharmacophore model. Simpler prototypes, viz. racemic 1-((2-hydroxynaphthalen-1-yl)arylmethyl)piperidin-4-ols, were first synthesized to develop kinetic resolution to pure enantiomers. Simultaneously, a series of racemic 1-((4-(2-(dialkylamino)ethoxy)phenyl)(2-hydroxynaphthalen-1-yl)methyl)piperidin-4-ols were evaluated against estrogen-responsive human MCF-7 breast cancer cells, but the compounds were found to be moderately active. The lack of potency could be due to the molecular bulk resulting in inadequate fit at the receptor. Subsequently, the molecular motif was modified to achiral 1-(4-(2-(dialkylamino)ethoxy)benzyl)naphthalen-2-ols by removing the piperidinol moiety. Bioevaluation of this new series of compounds displayed significantly enhanced cytotoxicity against MCF-7 cells. A representative compound for this series showed estrogen receptor alpha binding activity and the action is that of an antagonist. 相似文献